Cantor Fitzgerald Comments on PLRX FY2026 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Pliant Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($1.34) per share for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for Pliant Therapeutics' current full-year earnings is ($3.64) per share.

PLRX has been the subject of several other reports. Stifel Nicolaus lowered shares of Pliant Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Wells Fargo & Company cut their price objective on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 4th. Citigroup decreased their target price on Pliant Therapeutics from $4.00 to $1.50 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Leerink Partnrs downgraded Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Needham & Company LLC restated a "hold" rating and set a $10.00 price objective on shares of Pliant Therapeutics in a research note on Tuesday, March 4th. Twelve research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.31.

Pliant Therapeutics Stock Up 0.7%

Shares of Pliant Therapeutics stock traded up $0.01 on Tuesday, hitting $1.47. 405,033 shares of the company's stock traded hands, compared to its average volume of 1,117,658. Pliant Therapeutics has a 52-week low of $1.10 and a 52-week high of $16.10. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock has a market cap of $90.24 million, a P/E ratio of -0.44 and a beta of 1.35. The firm's 50-day moving average is $1.43 and its 200 day moving average is $5.90.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC increased its stake in shares of Pliant Therapeutics by 1,299.0% in the fourth quarter. Aquatic Capital Management LLC now owns 5,596 shares of the company's stock valued at $74,000 after purchasing an additional 5,196 shares during the period. BNP Paribas Financial Markets bought a new position in Pliant Therapeutics during the fourth quarter valued at about $99,000. KLP Kapitalforvaltning AS acquired a new position in Pliant Therapeutics during the fourth quarter worth about $108,000. Corton Capital Inc. bought a new stake in Pliant Therapeutics in the fourth quarter worth about $138,000. Finally, Atria Investments Inc lifted its holdings in Pliant Therapeutics by 18.1% in the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company's stock valued at $156,000 after acquiring an additional 1,812 shares during the last quarter. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.